Rodrigo Dienstmann

2010–2025 年に発表

92
論文数
18,894
被引用数
55
h 指数
83
i10 指数

被引用数

Rodrigo Dienstmann の年別被引用数1992 年: 被引用 1 件1993 年: 被引用 1 件2004 年: 被引用 3 件2007 年: 被引用 1 件2010 年: 被引用 1 件2011 年: 被引用 7 件2012 年: 被引用 15 件2013 年: 被引用 35 件2014 年: 被引用 67 件2015 年: 被引用 91 件2016 年: 被引用 152 件2017 年: 被引用 248 件2018 年: 被引用 236 件2019 年: 被引用 848 件2020 年: 被引用 966 件2021 年: 被引用 1,126 件2022 年: 被引用 934 件2023 年: 被引用 723 件2024 年: 被引用 1,052 件2025 年: 被引用 637 件2026 年: 被引用 39 件1994〜2003 年は被引用が無いため表示していません2005〜2006 年は被引用が無いため表示していません2008〜2009 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,998 件、この内訳の 18.2%中国: 引用元論文 1,420 件、この内訳の 12.9%イタリア: 引用元論文 744 件、この内訳の 6.8%イギリス: 引用元論文 709 件、この内訳の 6.5%ドイツ: 引用元論文 686 件、この内訳の 6.2%スペイン: 引用元論文 555 件、この内訳の 5%フランス: 引用元論文 480 件、この内訳の 4.4%オランダ: 引用元論文 391 件、この内訳の 3.6%日本: 引用元論文 334 件、この内訳の 3%スイス: 引用元論文 298 件、この内訳の 2.7%カナダ: 引用元論文 270 件、この内訳の 2.5%オーストラリア: 引用元論文 244 件、この内訳の 2.2%
0%18.2%その他 26%

分野

  • Medicine52.6%
  • Biochemistry, Genetics and Molecular Biology39.3%
  • Immunology and Microbiology2.5%
  • Computer Science1.9%
  • Chemistry0.7%
  • Neuroscience0.6%
  • その他2.4%

トピック

  • Cancer Genomics and Diagnostics7.3%
  • Colorectal Cancer Treatments and Studies5.8%
  • Genetic factors in colorectal cancer5.3%
  • Cancer Immunotherapy and Biomarkers4.8%
  • Cancer Cells and Metastasis3%
  • Lung Cancer Treatments and Mutations2.5%
  • その他71.3%

共著者

全論文

検索で開く
  1. The consensus molecular subtypes of colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , René Bernards, Stephen Friend, Pierre Laurent‐Puig, Jan Paul Medema, Anguraj Sadanandam, Lodewyk F.A. Wessels, Mauro Delorenzi, Scott Kopetz, Louis Vermeulen, Sabine Tejpar - Nature Medicine 2015 被引用: 5,259

  2. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 1,188

  3. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2018 被引用: 787

  4. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

    著者: , , , , , - Nature reviews. Cancer 2017 被引用: 1,030

  5. ESMO Guidance for Reporting Oncology real-World evidence (GROW)

    著者: , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 210

  6. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jason Walker, Benjamin M. Good, Chunlei Wu, Andrew I. Su, Rodrigo Dienstmann, Adam A. Margolin, David Tamborero, Núria López-Bigas, Steven J.M. Jones, Ron Bose, David H. Spencer, Lukas D. Wartman, Richard K. Wilson, Elaine R. Mardis, Obi L. Griffith - Nature Genetics 2017 被引用: 674

  7. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Olivier Déas, Jos Jonkers, Jean‐Yves Masson, Stefano Cairo, Jean‐Gabriel Judde, Mark J. O’Connor, Orland Dı́ez, Judith Balmañà, Violeta Serra - EMBO Molecular Medicine 2018 被引用: 274

  8. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paolo Nucíforo, Rodrigo Dienstmann, Chandra Verma, Núria López-Bigas, Maurizio Scaltriti, Mónica Arnedos, Cristina Saura, Violeta Serra - Nature Communications 2022 被引用: 120

  9. Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis

    著者: , , , , , , , , , , , , , , - European Radiology 2020 被引用: 205

  10. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Valentina Fornerone, Paola Gabaldi, Felix Haglund, Johan Hartman, Peter Horak, Tanja Jutzi, Mary Kasanicki, Simon Kreutzfeldt, Lucian Le Cornet, Rolf Lewensohn, Johan Lindberg, Carlos López, Andreas Lundqvist, Jose‐Ezequiel Martín, Gerrit A. Meijer, Susana Muñoz, Maud Ngo Camus, Claudio Nicotra, Paolo Nucíforo, Petra Oberrauch, Päivi Östling, Laura Pelz, Alejandro Piris‐Giménez, Elena Provenzano, Étienne Rouleau, John Rowell, Omar Saavedra, Giovanni Scoazec, Kenneth B. Seamon, Marc Tischkowitz, Lizet van der Kolk, Ruud van der Noll, María Vieito, Daniël J. Vis, Ana Vivancos, Christina von Gertten, Anders Wennborg, Lodewyk F.A. Wessels, Valtteri Wirta, Judith Balmañà, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Fröhling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile E. Voest, Jordi Rodón, Janne Lehtiö - Nature Cancer 2022 被引用: 130

  11. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 111

  12. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer

    著者: , , , , , , , , , , , , , - Annals of Oncology 2020 被引用: 150

  13. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

    著者: , , , , , , , , , - Annals of Oncology 2013 被引用: 366

  14. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alberto Bardelli, Josep Tabernero - JAMA Oncology 2018 被引用: 144

  15. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations

    著者: , , , , , , , , - Clinical Cancer Research 2018 被引用: 422

  16. Development of PI3K inhibitors: lessons learned from early clinical trials

    著者: , , , - Nature Reviews Clinical Oncology 2013 被引用: 766

  17. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joaquı́n Mateo, Joaquı́n Arribas, Rodrigo Dienstmann, Meritxell Bellet, Mafalda Oliveira, Cristina Saura, Sara Gutiérrez‐Enríquez, Judith Balmañà, Violeta Serra - Cancer Research 2022 被引用: 97

  18. Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

    著者: , , , - Molecular Cancer Therapeutics 2014 被引用: 465

  19. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

    著者: , , , , , , , , , - Annals of Oncology 2019 被引用: 266

  20. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raquel Pérez-López - Radiology 2021 被引用: 105

  21. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 101

  22. Early-Stage Breast Cancer Detection in Breast Milk

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2023 被引用: 58

  23. A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan M. Mockus, Olivier Elemento, Nikolaus Schultz, Núria López-Bigas, Mark Lawler, Jeremy Goecks, Malachi Griffith, Obi L. Griffith, Adam A. Margolin - Nature Genetics 2020 被引用: 176

  24. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma

    著者: , , , , , , , , , , , , , , , , - Clinical Cancer Research 2022 被引用: 65